154 related articles for article (PubMed ID: 23548379)
1. Intravitreal bevacizumab for radiation-induced cystoid macular oedema in patients with nasopharyngeal carcinoma: a clinical series.
Subrayan V; Khaw KW; Peyman M; Koay AC; Tajunisah I
Ophthalmologica; 2013; 229(4):208-11. PubMed ID: 23548379
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal dexamethasone implant in radiation-induced macular oedema.
Frizziero L; Parrozzani R; Trainiti S; Pilotto E; Miglionico G; Pulze S; Midena E
Br J Ophthalmol; 2017 Dec; 101(12):1699-1703. PubMed ID: 28404670
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity.
Kim M; Jeong S; Sagong M
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):691-697. PubMed ID: 27796671
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial.
Ahmadieh H; Nourinia R; Hafezi-Moghadam A; Sabbaghi H; Nakao S; Zandi S; Yaseri M; Tofighi Z; Akbarian S
Br J Ophthalmol; 2019 Jul; 103(7):922-927. PubMed ID: 30150280
[TBL] [Abstract][Full Text] [Related]
5. Monthly intravitreal bevacizumab for macular edema after iodine-125 plaque radiotherapy of uveal melanoma.
Mashayekhi A; Rojanaporn D; Al-Dahmash S; Shields CL; Shields JA
Eur J Ophthalmol; 2014; 24(2):228-34. PubMed ID: 23934823
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
7. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.
Arevalo JF; Sanchez JG; Wu L; Maia M; Alezzandrini AA; Brito M; Bonafonte S; Lujan S; Diaz-Llopis M; Restrepo N; Rodríguez FJ; Udaondo-Mirete P;
Ophthalmology; 2009 Aug; 116(8):1488-97, 1497.e1. PubMed ID: 19545900
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group.
Arevalo JF; Lasave AF; Wu L; Acon D; Farah ME; Gallego-Pinazo R; Alezzandrini AA; Fortuna V; Quiroz-Mercado H; Salcedo-Villanueva G; Maia M; Serrano M; Rojas S;
Br J Ophthalmol; 2016 Dec; 100(12):1605-1610. PubMed ID: 26912377
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab associated with grid laser photocoagulation in macular edema secondary to branch retinal vein occlusion.
Salinas-Alamán A; Zarranz-Ventura J; Caire González-Jauregui JM; Sádaba-Echarri LM; Barrio-Barrio J; García-Layana A
Eur J Ophthalmol; 2011; 21(4):434-9. PubMed ID: 21140369
[TBL] [Abstract][Full Text] [Related]
10. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
[TBL] [Abstract][Full Text] [Related]
11. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
[TBL] [Abstract][Full Text] [Related]
12. Macular cystic changes as predictive factor for the recurrence of macular oedema in branch retinal vein occlusion.
Tilgner E; Dalcegio Favretto M; Tuisl M; Wiedemann P; Rehak M
Acta Ophthalmol; 2017 Nov; 95(7):e592-e596. PubMed ID: 28266152
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J;
Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025
[TBL] [Abstract][Full Text] [Related]
14. CHANGES IN CENTRAL CHOROIDAL THICKNESS AFTER TREATMENT OF DIABETIC MACULAR EDEMA WITH INTRAVITREAL BEVACIZUMAB CORRELATION WITH CENTRAL MACULAR THICKNESS AND BEST-CORRECTED VISUAL ACUITY.
Nourinia R; Ahmadieh H; Nekoei E; Malekifar P; Tofighi Z
Retina; 2018 May; 38(5):970-975. PubMed ID: 28426622
[TBL] [Abstract][Full Text] [Related]
15. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema.
Kim M; Lee P; Kim Y; Yu SY; Kwak HW
Ophthalmologica; 2011; 226(3):138-44. PubMed ID: 21822008
[TBL] [Abstract][Full Text] [Related]
16. High-dose (2.0 mg) intravitreal ranibizumab for recalcitrant radiation retinopathy.
Finger PT; Chin KJ
Eur J Ophthalmol; 2013; 23(6):850-6. PubMed ID: 23813109
[TBL] [Abstract][Full Text] [Related]
17. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME;
Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal injection of methotrexate in persistent diabetic macular edema: a 6-month follow-up study.
Falavarjani KG; Golabi S; Modarres M
Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2159-2164. PubMed ID: 27145784
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results.
Arevalo JF; Maia M; Garcia-Amaris RA; Roca JA; Sanchez JG; Berrocal MH; Wu L;
Ophthalmology; 2009 Aug; 116(8):1481-7, 1487.e1. PubMed ID: 19545901
[TBL] [Abstract][Full Text] [Related]
20. "Off-label" use of intravitreal bevacizumab in non-ischemic macular edema secondary to retinal vein obstructions.
Dascalu AM; Popa-Cherecheanu A; Popa-Cherecheanu M; Nica A; Serban D
Rom J Ophthalmol; 2016; 60(2):90-95. PubMed ID: 29450329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]